Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2014-07-18
2018-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
New technologies will allow measurement of a broad range of bacteria and metabolites, to test if the clinical response to EEN and changes in gut inflammation are associated with bacterial composition and chemical products; and if maintenance of changes using SEN reduces the risk of relapse over a 12 month period.
The study will aim to recruit all potential Crohn's disease children coming to a tertiary paediatric centre for colonoscopy. Once consented, an initial blood, urine and faecal sample will be requested along with 8 mucosal biopsies during the routine endoscopy session. If diagnosed with CD, and if the clinician prescribes treatment with EEN, an additional blood sample will be requested at the end of EEN, and 5 faecal and urine samples spread over 12 months; as well as some dietary information.
Samples will be collected from up to 42 children with CD and 42 age- and sex-matched healthy volunteers. Initial samples taken from children who were not diagnosed with CD will be compared with CD samples to look for potential metabolic disease markers. Characterisation of faecal bacteria and metabolites in both faeces and urine; as well as measurement of blood inflammatory biomarkers will be performed.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Impact of "Crohn's Disease-TReatment-with-EATing" Diet and Exclusive Enteral Nutrition on Healthy Gut Bacteria
NCT02426567
CD-TREAT Diet: a Novel Therapy for Active Luminal Crohn's Disease
NCT03171246
The Intensive Post Exclusive Enteral Nutrition Study
NCT04225689
Biologics and Partial Enteral Nutrition Study
NCT04859088
Dietary Therapy and Gut Microbiome in Crohn's Disease and Ulcerative Colitis
NCT02412553
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study design will build on previous work by looking at differences in both the gut bacteria (faecal and mucosal) and bacterial metabolic activity at different stages of disease activity. Changes in bacterial composition between disease groups will be examined; between Crohn's disease children on different treatments; and between different sites in the gut. Crohn's disease biomarkers in faeces and urine will also be assessed by analysing bacterial metabolites.
Up to a total of 42 children with Crohn's Disease will be recruited. 42 healthy children will also be recruited to provide a faecal and urine sample, to show the normal variety of gut bacteria and metabolites in healthy children for comparison.
Children who underwent colonoscopy but did not have Crohn's disease will be used as a comparison group to try and identify Crohn's disease bacterial signatures from faeces and urine, and as a non-Crohn's disease control group for comparison of mucosal biopsies.
Recruitment Three groups of children will participate in this study. A. Children undergoing endoscopic investigations (colonoscopy) for colonic inflammation including Crohn's disease \[children who are found not to have Crohn's disease will not participate in the follow up aspect (during treatment with EEN) of this study\].
B. Previously diagnosed patients with Crohn's disease due to start an 8 week standard course of treatment with EEN due to disease flare up.
C. Healthy children unrelated to Crohn's disease patients will be used as a control group.
Groups A and B: an initial blood, urine, faecal sample followed by 5 further faecal and urine samples over 12 months; and dietary information.
\[Group A will also have 8 mucosal biopsies taken during routine endoscopy\]. During treatment with EEN (clinical decision), an additional blood sample will be requested during routine blood sampling at start and end of treatment.
Group C: 1 urine and faecal sample will be requested.
All groups will have height, weight and grip strength measured at baseline. Participant receiving EEN will have this repeated 60 days after start of treatment and 60 days after end of treatment.
Detailed Methods Preliminary health check by means of a short health questionnaire - basic health information, age, any medication.
Mucosal samples: in newly diagnosed patients having a colonoscopy for diagnostic purposes, an additional 6 mucosal biopsy samples; 2 from the terminal ileum when possible, 2 from the proximal colon and 2 from the distal colon will be taken (14-16 are collected at normal colonoscopy). An additional 2 biopsy samples will also be collected from the duodenum during upper endoscopy.
Dietary information: habitual dietary intake and eating patterns assessed using validated Food Frequency Questionnaire (FFQ); a 5 step multiple pass 24 hour dietary recall questionnaire for data on actual diet at time of faecal and urine sampling.
EEN compliance (groups A\&B only): completion of short EEN compliance questionnaire at 28 day and 56 day time points.
Medication and Disease History: information on disease activity, medication and medical history collected from medical notes.
Lab Assays Bacterial diversity: The gut bacterial diversity and composition from stool samples will be measured using molecular techniques such as quantitative polymerase chain reaction (PCR) from bacterial ribosomal DNA and next generation sequencing (metagenomics). These techniques will also be used to look at the composition of bacteria associated with mucosal tissue biopsies. Changes in overall gut bacteria composition using standard numerical indices will be measured across the 6 faecal samples collected over the 12 month period, as well as between groups.
Bacterial metabolism: A large number of different products from bacterial metabolism, such as short chain fatty acids, sulphide, and ammonia will be measured using a range of techniques including gas chromatography and gas chromatography mass spectrometry (GCMS) (metabolomics). Faecal pH, a marker of bacterial fermentation, will also be measured.
Disease markers: Other disease markers and metabolites such as faecal calprotectin, will be measured from faecal samples .
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A) Newly diagnosed with Crohn's disease
Children undergoing endoscopic investigations (colonoscopy) for colonic inflammation including Crohn's disease \[children who are found not to have Crohn's disease will not participate further\].
\[Intervention - clinical, not research decision - Exclusive Enteral Nutrition for 8 weeks; usually 330ml 6 times per day\] per day
Exclusive Enteral Nutrition (EEN)
8 week standard course of treatment with EEN
B) Existing diagnosis of Crohn's disease
Previously diagnosed patients with Crohn's disease due to start an 8 week standard course of treatment with EEN due to disease flare up.
\[Intervention - clinical, not research decision - Exclusive Enteral Nutrition for 8 weeks; usually 330ml 6 times per day\]
Exclusive Enteral Nutrition (EEN)
8 week standard course of treatment with EEN
c) Healthy control group
Healthy children unrelated to Crohn's disease patients No intervention
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exclusive Enteral Nutrition (EEN)
8 week standard course of treatment with EEN
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Group B: children with existing Crohn's Disease about to undergo treatment with EEN
* Group C: healthy volunteers up to age 17 years willing to provide one urine and stool sample
Exclusion Criteria
* children found not to have Crohn's Disease after colonoscopy will not be required to take any further part in the study
3 Years
17 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Glasgow
OTHER
NHS Greater Glasgow and Clyde
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NHS Greater Glasgow & Clyde - Royal Hospital for Sick Children
Glasgow, , United Kingdom
NHS Ayrshire & Arran - University Hospital Crosshouse
Kilmarnock, , United Kingdom
NHS Forth Valley - Forth Valley Royal Hospital
Larbert, , United Kingdom
NHS Greater Glasgow & Clyde - Royal Alexandra Hospital
Paisley, , United Kingdom
NHS Lanarkshire - Wishaw General Hospital
Wishaw, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Lawrence Armstrong
Role: primary
Ghassan Al-Hourani
Role: primary
Mohammed Iqbal
Role: primary
Caroline Delahunty
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Logan M, MacKinder M, Clark CM, Kountouri A, Jere M, Ijaz UZ, Hansen R, McGrogan P, Russell RK, Gerasimidis K. Intestinal fatty acid binding protein is a disease biomarker in paediatric coeliac disease and Crohn's disease. BMC Gastroenterol. 2022 May 23;22(1):260. doi: 10.1186/s12876-022-02334-6.
Gkikas K, Logan M, Nichols B, Ijaz UZ, Clark CM, Svolos V, Gervais L, Duncan H, Garrick V, Curtis L, Buchanan E, Cardigan T, Armstrong L, Delahunty C, Flynn DM, Barclay AR, Tayler R, Milling S, Hansen R, Russell RK, Gerasimidis K. Dietary triggers of gut inflammation following exclusive enteral nutrition in children with Crohn's disease: a pilot study. BMC Gastroenterol. 2021 Dec 3;21(1):454. doi: 10.1186/s12876-021-02029-4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GN14KH275
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.